SCHEMBL8385486

SCHEMBL8385486

CCOc1cccc(C(=O)Nc2ccc3[nH]cc(C4CCN5CCCCC5C4)c3c2)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.53
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
HTR1D P28221 15/20 0.49
HTR1B P28222 12/20 0.49
HTR1A P08908 2/20 0.49
HTR1F P30939 2/20 0.49
CHRM2 P08172 1/20 0.46
DRD2 P14416 1/20 0.46
POLB P06746 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30908867 1.00 RORC (0.53) RORCNPC1RAB9AKMT2AMEN1
SCHEMBL30909007 0.87 RORC (0.53) RORCHTR1DHTR1BHTR1AHTR1F
SCHEMBL8383584 0.87 RORC (0.53) RORCHTR1DHTR1BHTR1AHTR1F
SCHEMBL30909175 0.87 HTR1D (0.53) RORCHTR1DHTR1BHTR1AHTR1F
SCHEMBL8386464 0.87 HTR1D (0.53) RORCHTR1DHTR1BHTR1AHTR1F
SCHEMBL8382133 0.86 HTR1D (0.50) NPC1RAB9AKMT2AMEN1HTR1D
SCHEMBL8387192 0.86 HTR1D (0.57) RORCHTR1DHTR1BHTR1AHTR1F
SCHEMBL8386924 0.85 RORC (0.55) RORCHTR1DHTR1BHTR1AHTR1F
SCHEMBL30909279 0.85 RORC (0.55) RORCHTR1DHTR1BHTR1AHTR1F
Hydrochloric Acid SCHEMBL8386523 0.85 HTR1D (0.56) RORCHTR1DHTR1BHTR1AHTR1F

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
US-5874427-A MIGRAINE ELI LILLY AND COMPANY (US) 1999-02-23 US disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D RORC 1266/4885NPC1 2590/4885RAB9A 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.